<DOC>
	<DOCNO>NCT01391338</DOCNO>
	<brief_summary>In study several dos ASP3652 , give orally 12 week , compare placebo treatment patient Chronic abacterial Prostatitis / Chronic Pelvic Pain Syndrome .</brief_summary>
	<brief_title>A Clinical Study Investigate Efficacy , Safety Pharmacokinetics ASP3652 Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome ( CP/CPPS )</brief_title>
	<detailed_description>This study investigate efficacy ASP3652 treatment patient Chronic abacterial Prostatitis / Chronic Pelvic Pain Syndrome ( CP/CPPS ) . In comparison placebo , ASP3652 give different dosage orally 12 week . The aims investigate efficacy ASP3652 CP/CPPS , ass optimal dose ASP3652 , investigate safety tolerability investigate pharmacokinetics pharmacodynamics ASP3652 patient CP/CPPS out-patients set .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Prostatitis</mesh_term>
	<criteria>Is diagnose CP/CPPS symptom least 3 month last 6 month Has NIHCPSI total score least 15 A score least 4 question 4 ( pain ) NIHCPSI Reports pain palpation prostate perineum/genital area Answers `` yes '' least 1 6 item question 1 2 NIHCPSI Is willing comply study requirement complete micturition symptom diary attend study visit Isolated unilateral testicular , penile scrotal pain solitary symptom pelvic pain Urinary Tract Infection ( UTI ) prostate infection find screen use pre post massage test last 3 month prior screen Any prior prostate bladder intervention within 3 month prior screen Lower urinary tract malignancy ( suspect ) , positive ( micro ) hematuria urine sediment Prostate Specific Antigen ( PSA ) &gt; 4 ng/mL Symptomatic urethral stricture symptomatic bladder urethral calculus , severe bladder outlet obstruction , overactive bladder incontinence Post Void Residual volume , great 150 mL Clinically significant abnormality transabdominal ultrasound bladder prostate neurological disease defect affect bladder function Currently active sexually transmittable disease Substance abuse use delta9tetrahydrocannabinol ( THC ) assess positive urine test THC screen Major depression , i.e . Center Epidemiological Studies Depression Scale score 27 Any clinically relevant concomitant disease ( past present ) would , opinion investigator , put subject risk mask measure efficacy Use steroid , immunomodulators , anticonvulsant , cytochrome P4502C8 inhibitor , cannabis/THC base medication , opioid analgetics antiviral/antimicrobial/antifungal agent last 4 week screen Initiation , discontinuation , variation dose antidepressant , alphablockers , 5alpha reductase inhibitor , antimuscarinics , benzodiazepine , skeletal muscle relaxant , nonsteroidal antiinflammatory drug , nonopioid analgetics herbal therapy last 4 week screen . Subjects continue medication stable dose throughout study Clinically relevant abnormal urine blood safety laboratory value active hepatic and/or biliary disease ( AST ALT &gt; 3 time upper limit normal , total bilirubin &gt; 2 time upper limit normal ) Participated clinical study treat investigational drug device within 30 day prior screen , period stipulate local regulation , whichever long</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Prostatitis</keyword>
	<keyword>Chronic</keyword>
	<keyword>Pelvic Pain</keyword>
	<keyword>NIH-CPSI</keyword>
	<keyword>Pain domain score NIH-CPSI</keyword>
</DOC>